NCT07027254View on ClinicalTrials.gov

PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism

NARecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

December 1, 2027

Conditions
Primary AldosteronismSecondary HypertensionAldosterone-Producing AdenomaIdiopathic HyperaldosteronismAdrenalectomy
Interventions
DIAGNOSTIC_TEST

68Ga-pentixafor PET/CT

Diagnostic PET/CT imaging using gallium-68 labeled pentixafor to assess adrenal CXCR4 expression in patients with primary aldosteronism. The imaging is performed prior to treatment allocation and used to assist lateralization of aldosterone production when combined with adrenal venous sampling (AVS).

Trial Locations (2)

06351

RECRUITING

Samsung Medical Center, Seoul

03080

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Samsung Medical Center

OTHER

lead

Seoul National University Hospital

OTHER

NCT07027254 - PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism | Biotech Hunter | Biotech Hunter